Zai Lab Limited - ZLAB
About Gravity Analytica
Recent News
- 01.12.2026 - Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
- 01.12.2026 - Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
- 01.12.2026 - Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
- 01.12.2026 - Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
- 01.12.2026 - Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
- 01.12.2026 - Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
- 01.12.2026 - Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
- 01.12.2026 - Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
- 01.12.2026 - Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
- 01.12.2026 - Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference